Status: Recruiting
Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients
This is a prospective, open, multiple-center clinical study of renal preservation therapy in high-risk upper urinary tract urothelial carcinoma patients . The study was conducted in accordance with the Good Practice for Quality Control of Clinical Trials for Pharmaceutical Products (GCP). Approximately 20 subjects will be enrolled to evaluate the efficacy and safety of RC48 (2.0 mg/kg intravenously every 3 weeks) combined with Tislelizumab (200mg intravenously every 3 weeks).
Participants needed: 20
Trial details
Phase: Phase 2Age: 18-90Biological sex: AllType: InterventionalSponsor: RenJi HospitalUpdated: Dec 9, 2025Locations: 1
Eligibility criteria
ECOG 0~2; [+15]
Previously received anti-PD-1, anti-PD-L1, anti-PD-L2 therapy, including adjuvan... [+17]